Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a
- PMID: 24416596
- PMCID: PMC3876677
- DOI: 10.1155/2013/746749
Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a
Abstract
VEGF-A is the most potent angiogenic factor in tumour angiogenesis. Its effects are mediated via two receptors VEGFR-1 and VEGFR-2. Primary aim of our study was to examine the expression of VEGFR-1 in breast cancer and its correlation to VEGF expression, lymph node status, tumour size, histological grade, and hormone receptor status. To examine the VEGFR-1 and VEGF expressions in tumour and surrounding tissue of 51 breast cancer patients, and in healthy breast tissue of 30 benign breast diseases patients, we used three-step immunohistochemical staining. VEGFR-1 and VEGF expressions were significantly increased in breast cancer tumour in relation to surrounding tissue (P < 0.01), and the VEGF expression was significantly increased in lymph node positive breast cancer patients (P < 0.01). VEGFR-1 and VEGF expressions were significantly higher in breast cancer tumour compared with healthy breast tissue (P < 0.01). Significant correlation between VEGF and VEGFR-1 expressions was found (P < 0.05). No significant correlations between VEGF and VEGFR-1 expressions and tumour size, histological grade, and hormone receptor status were found. Increased expression of VEGFR-1 and VEGF in breast cancer tumour and significant correlation between these proteins suggest the possible role of VEGF/VEGFR-1 signalization in breast cancer development, although VEGFR-1 potential prognostic value was not confirmed.
Figures
Similar articles
-
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.J Pathol. 2003 Jun;200(2):183-94. doi: 10.1002/path.1339. J Pathol. 2003. PMID: 12754739
-
Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.Adv Clin Exp Med. 2017 Mar-Apr;26(2):245-249. doi: 10.17219/acem/58784. Adv Clin Exp Med. 2017. PMID: 28791841
-
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.Histopathology. 2012 Sep;61(3):350-64. doi: 10.1111/j.1365-2559.2012.04223.x. Epub 2012 Jun 13. Histopathology. 2012. PMID: 22690749
-
Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.Dan Med J. 2013 Apr;60(4):B4626. Dan Med J. 2013. PMID: 23651727 Review.
-
Revisiting VEGF/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?J Drug Target. 2025 May 23:1-24. doi: 10.1080/1061186X.2025.2508985. Online ahead of print. J Drug Target. 2025. PMID: 40387416 Review.
Cited by
-
Proteogenomic Analysis of Breast Cancer Transcriptomic and Proteomic Data, Using De Novo Transcript Assembly: Genome-Wide Identification of Novel Peptides and Clinical Implications.Mol Cell Proteomics. 2022 Apr;21(4):100220. doi: 10.1016/j.mcpro.2022.100220. Epub 2022 Feb 26. Mol Cell Proteomics. 2022. PMID: 35227895 Free PMC article.
-
Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer.J Clin Med. 2023 Mar 21;12(6):2412. doi: 10.3390/jcm12062412. J Clin Med. 2023. PMID: 36983412 Free PMC article. Review.
-
Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.Am J Cancer Res. 2024 Sep 15;14(9):4172-4196. doi: 10.62347/KIVS3169. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417188 Free PMC article. Review.
-
MACC1 as a Potential Target for the Treatment and Prevention of Breast Cancer.Biology (Basel). 2023 Mar 16;12(3):455. doi: 10.3390/biology12030455. Biology (Basel). 2023. PMID: 36979146 Free PMC article. Review.
-
A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients.Oncotarget. 2017 Jan 17;8(3):5460-5473. doi: 10.18632/oncotarget.12348. Oncotarget. 2017. PMID: 27705924 Free PMC article.
References
-
- Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. The New England Journal of Medicine. 2005;353(17):1784–1792. - PubMed
-
- Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine. 1971;285(21):1182–1186. - PubMed
-
- Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth and Differentiation. 2001;12(3):129–135. - PubMed
-
- Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology. 2002;20(21):4368–4380. - PubMed
-
- Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nature Medicine. 2003;9(6):669–676. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources